๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

SOX

Also listed in trial records as Normal
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 10 trials in our China register that name SOX as an intervention. Synced 25 Sep 2026
10Trials tracked
5Recruiting now
9Lead sponsors
1Country register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

SOX is named as a drug or biological intervention in 10 clinical trials in our China trial register, 5 of which are recruiting. Lead sponsors include The First Affiliated Hospital with Nanjing Medical University (2), The Second Affiliated Hospital of Fujian Medical University (1) and Henan Cancer Hospital (1). Registered phases: Phase 2, Phase 3 and Observational. Conditions studied include Gastric Cancer; Stomach Neoplasms; Digestive System Neoplasms.

01

Clinical trials of SOX

10 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06371586 Neo-Sequence 2๏ผšNCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC (ClinicalTrials.gov ↗)
Gastric Cancer, Diffuse Type Carcinoma
Phase 2 Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences China
NCT06685887 A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis (ClinicalTrials.gov ↗)
Gastric Cancer
Phase 2 Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology China
NCT07007182 Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer (ClinicalTrials.gov ↗)
Gastric Adenocarcinoma, Stomach Neoplasms
Phase 2 Recruiting Jinbo Yue China
NCT07474324 Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage โ…ข Gastric Cancer: A Prospective, Multicenter, Randomized, Phase โ…ก Clinical Trial (ClinicalTrials.gov ↗)
GC/GEJC
Phase 2 Recruiting The First Affiliated Hospital with Nanjing Medical University China
NCT06760858 A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer (ClinicalTrials.gov ↗)
Gastric Cancer, Gastroesophageal Junction Cancer
Observational Recruiting Southwest Hospital, China China
NCT07068516 Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer (ClinicalTrials.gov ↗)
Gastric Cancer Stage
Phase 3 Not yet open Xiangdong Cheng China
NCT07391826 Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX (ClinicalTrials.gov ↗)
Stage III Gastric Cancer
Phase 2 Not yet open The First Affiliated Hospital with Nanjing Medical University China
NCT07607210 A Clinical Study of SHR-1701 Combined With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Siewert Type II Adenocarcinoma of the Esophagogastric Junction (ClinicalTrials.gov ↗)
Siewert Type II Adenocarcinoma of the Esophagogastric Junction
Phase 2 Not yet open Hebei Medical University Fourth Hospital China
NCT05177068 Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer (ClinicalTrials.gov ↗)
Gastric Cancer
Phase 2 Active, closed Henan Cancer Hospital China
NCT05602935 Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
Stomach Neoplasms, Digestive System Neoplasms, Neoplasms
Phase 2 Active, closed The Second Affiliated Hospital of Fujian Medical University China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

12 conditions
Condition (as registered)Trials
Gastric Cancer3
Stomach Neoplasms2
Digestive System Neoplasms1
Neoplasms1
Digestive System Diseases1
Gastric Cancer Stage1
Siewert Type II Adenocarcinoma of the Esophagogastric Junction1
Gastric Adenocarcinoma1
Diffuse Type Carcinoma1
GC/GEJC1
Gastric Cancer, Gastroesophageal Junction Cancer1
Stage III Gastric Cancer1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
The First Affiliated Hospital with Nanjing Medical University2
The Second Affiliated Hospital of Fujian Medical University1
Henan Cancer Hospital1
Xiangdong Cheng1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1
Hebei Medical University Fourth Hospital1
Jinbo Yue1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences1
Southwest Hospital, China1
04

Trials by country register

RegisterSOX trials
Clinical trials in China10

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how SOX works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SOX (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.